Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes

Titanium Endoclips (TE) are safe and not expensive. It has been applied in various tissues of the human body due to its high histocompatibility and no foreign body reaction. TE has also been used as a fiducial marker to assist radiotherapy in several tumors, helping the detection of the target area, reducing the damage to healthy tissues (1). When radiotherapy is planned, the inability to visualize the exact tumor location, due to the bladder wall movement, is by far the biggest challenge to be overcome. The search for the ideal fiducial marker is ongoing in bladder cancer, but today, despite the use of different agents and materials, (2-5) no ideal strategy was found. The concept to guide radiotherapy in partial bladder treatment opens perspectives for future studies to explore the benefits with its use. Among these benefits, it is noteworthy that partial bladder radiotherapy allows the increase of dose in a reduced volume of the organ based on the rationale of improving the local control, without a significant increase in toxicity (6). Currently, partial bladder radiotherapy is performed using findings from cystoscopy, and pre-surgical tomography (CT) or magnetic resonance (MRI) (7) but The clinical target volume (CTV) delimitation on the planning CT based on pre-surgical images brings uncertainty about the exact tumor boundaries (8). Consequently, to avoid tumor geographic missing, large margins on the CTV to generate the planning tumor volume (PTV) are required (9). The PTV with large volumes limits dose escalation due to the excessive risk of late complications. Thus, the endoscopic bladder fiducials to delimit the CTV give more precision to delineate the target allowing a reduced and more accurate CTV. Today, there are several forms of image-guided radiotherapy (IGRT) (10). The association between fiducial and IGRT would guarantee more precision to deliver the radiotherapy beam to the target. Among the IGRT system available, in special, IGRT with cone-beam CT combined with bladder fiducials would allow not only a reduction of margins with great precision, but it would also serve as an instrument to control the bladder volume during the radiotherapy fractions, translating in a more significant and realistic relationship between radiotherapy planning and treatment for the prediction of late complications (11). Adaptive radiotherapy combining the cone-beam CT images and treatment planning information still being developed, and in theory, has the potential of improving therapeutic ratio for bladder preservation. In this scenario, the bladder fiducial can have great value to adapt the treatment to the plans (10, 12, 13). On the other hand, even using simpler IGRT systems, such as planar images from kilovoltage or megavoltage sources, the bladder fiducial also brings precision in controlling the tumor bed’s positioning EDITORIAL COMMENT Vol. 47 (1): 100-102, January February, 2021

[1]  T. D. de Reijke,et al.  BioXmark® liquid fiducial markers for image guided radiotherapy in muscle invasive bladder cancer, a safety and performance trial. , 2020, The British journal of radiology.

[2]  Muhammad Shahbaz,et al.  Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes , 2020, International braz j urol : official journal of the Brazilian Society of Urology.

[3]  T. D. de Reijke,et al.  The feasibility and utility of cystoscopy-guided hydrogel marker placement in patients with muscle invasive bladder cancer. , 2019, Practical radiation oncology.

[4]  Morten Høyer,et al.  Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer , 2014, Acta oncologica.

[5]  M. Meng,et al.  Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes , 2014, PloS one.

[6]  D. Dearnaley,et al.  Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  Peter Remeijer,et al.  Adaptive management of bladder cancer radiotherapy. , 2010, Seminars in radiation oncology.

[8]  P. Jenkins,et al.  Defining the clinical target volume for bladder cancer radiotherapy treatment planning. , 2009, International journal of radiation oncology, biology, physics.

[9]  D. Jaffray,et al.  Advances in image-guided radiation therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ali Amer,et al.  Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction. , 2006, International journal of radiation oncology, biology, physics.

[11]  V. Khoo,et al.  Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[12]  D. Hunt,et al.  Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. , 2014, International braz j urol : official journal of the Brazilian Society of Urology.

[13]  J. Logue,et al.  Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. , 2005, Seminars in radiation oncology.

[14]  D. Ash,et al.  Radiation treatment planning for bladder cancer: a comparison of cystogram localisation with computed tomography. , 1983, Clinical radiology.